Insulin patch pump

Information

  • Patent Grant
  • 11033677
  • Patent Number
    11,033,677
  • Date Filed
    Tuesday, April 30, 2019
    4 years ago
  • Date Issued
    Tuesday, June 15, 2021
    2 years ago
Abstract
A user-wearable patch pump system for delivery of insulin or other medicament can include a pump and an attachment portion that attaches the pump to a user's body. The pump can include a drive unit and a disposable cartridge containing a medicament with the drive unit configured to cause the pump to deliver the medicament in the cartridge to the user. The attachment portion can include a retention frame configured to selectively retain the pump therein and an adhesive patch configured to be attached to the user's body. The pump can be selectively attached to the retention frame and used to deliver medicament either through a cannula to an infusion site directly beneath the retention frame or through tubing to an infusion site displaced from the retention frame.
Description
FIELD OF THE INVENTION

The present invention relates to medical pumps for delivering medicament to a patient and, more specifically, to a user-wearable insulin patch pump for delivering insulin to a patient.


BACKGROUND OF THE INVENTION

There are many applications in academic, industrial, and medical fields that benefit from devices and methods that are capable of accurately and controllably delivering fluids, such as liquids and gases, that have a beneficial effect when administered in known and controlled quantities. Such devices and methods can be particularly useful in the medical field where treatments for many patients include the administration of a known amount of a substance at predetermined intervals.


One category of devices for delivering such fluids is that of pumps that have been developed for the administration of insulin and other medicaments for those suffering from both type I and type II diabetes. Some pumps configured as portable infusion devices can provide continuous subcutaneous medicament injection and/or infusion therapy for the treatment of diabetes. Such therapy may include, e.g., the regular and/or continuous injection or infusion of insulin into the skin of a person suffering from diabetes and offer an alternative to multiple daily injections of insulin by an insulin syringe or an insulin pen. Such pumps can be ambulatory/portable infusion pumps that are worn by the user and may use replaceable cartridges. Examples of such pumps and various features that can be associated with such pumps include those disclosed in U.S. patent application Ser. No. 13/557,163, U.S. patent application Ser. No. 12/714,299, U.S. patent application Ser. No. 12/538,018, U.S. patent application Ser. No. 13/838,617, U.S. patent application Ser. No. 13/827,707 and U.S. Pat. No. 8,287,495, each of which is hereby incorporated herein by reference in its entirety.


One type of pump that has been developed is a patch pump, or micro pump. Patch pumps are small pumps, typically ambulatory, that are carried directly on the skin under the user's clothing. Such a pump generally is situated directly on the injection site such that no tubing is required to deliver the insulin or other medicament to the patient. Patch pumps typically are at least in part disposable, meant to be worn for a day or two and then discarded for a new patch pump.


SUMMARY

A user-wearable patch pump system for delivery of insulin or other medicament can include a pump and an attachment portion that attaches the pump to a user's body. The pump can include a drive unit and a disposable cartridge containing a medicament with the drive unit configured to cause the pump to deliver the medicament in the cartridge to the user. The attachment portion can include a retention frame configured to selectively retain the pump therein and an adhesive patch configured to be attached to the user's body.


In one embodiment, the user-wearable patch pump system can include both tubing configured to extend between the retention frame and an infusion site displaced from the retention frame and a cannula configured to extending into an infusion site directly beneath the retention frame. In such an embodiment, the pump can be selectively attached to the retention frame and used to deliver medicament either through the cannula to the infusion site directly beneath the retention frame or through the tubing to the infusion site displaced from the retention frame. Such a configuration provides the user with the flexibility of using multiple infusion sites with a single point of attachment of the pump on the body.


In some embodiments, the retention frame can include a sealing membrane. The sealing membrane can provide an opening through the frame configured to receive a removable needle for insertion of a cannula that can be used to deliver medicament. In other embodiments, the retention frame can include a receiving slot configured to receive a connector of a standard infusion set. In such embodiments, the cannula of the infusion set can then be used to deliver medicament.


In various embodiments, the pump can attach to and be retained by the frame in a variety of different ways. In some embodiments, the pump is mated with the retention frame in a generally vertical manner to cause one or more tabs on the frame to snap into engagement with one or more recesses on the pump. In one such embodiment, the frame includes a first tab configured as a hook portion and a second tab configured as a snap portion. The pump can be engaged with the frame by first inserting a first recess in the pump onto the hook portion and then rotating the pump downwardly about the hook portion to engage a second recess in the pump with the snap portion. In other embodiments, the pump can be generally horizontally, slidably received by the frame, such as by engaging elongate recesses along the sides of the pump with elongate tabs on the frame or by engaging an elongate recess on a bottom of the pump with an elongate upwardly extending projection on the frame. In a further embodiment, the frame can include a rotatable cleat such that engaging a recess on the pump with the cleat and then turning the pump on the cleat locks the pump onto the frame.


Certain embodiments are described further in the following description, examples, claims, and drawings. These embodiments will become more apparent from the following detailed description when taken in conjunction with the accompanying exemplary drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A-1F are perspective views of portions of a patch pump system according to an embodiment of the present invention.



FIGS. 2A-2F are perspective views of portions of a patch pump system according to an embodiment of the present invention.



FIGS. 3A-3F are perspective views of portions of a patch pump system according to an embodiment of the present invention.



FIGS. 4A-4F are perspective views of portions of a patch pump system according to an embodiment of the present invention.



FIGS. 5A-5D are perspective views of portions of a patch pump system according to an embodiment of the present invention.



FIGS. 6A-6E are perspective views of portions of a patch pump system according to an embodiment of the present invention.



FIG. 7 is a screen shot of a control screen for a control device for controlling a patch pump according to an embodiment of the present invention.



FIGS. 8A-8F are views of portions of a patch pump system according to an embodiment of the present invention.





DETAILED DESCRIPTION OF THE DRAWINGS


FIGS. 1A-1F depict a patch pump 100 according to one embodiment of the invention.


Patch pump 100 includes a pump 102 and an attachment portion 104 that enables the attachment of the pump 104 to the user.


The attachment portion 104 of patch pump, depicted most clearly in FIGS. 1A and 1B, includes a retention frame 106 affixed to an adhesive patch 108 and a removable needle 110. In one embodiment, the retention frame 106 is preattached to the adhesive patch 108 with, for example, glue or other suitable adhesive or technique. In other embodiments, the retention frame 106 can be removably attachable with the adhesive patch 108 or can be permanently attached to the retention frame 106 by the user. In certain embodiments, the retention frame 106 can comprise polypropylene, polycarbonate or Cyclic Insulin Copolymer (COC). In general, retention frame 106 can comprise any flexible and fatigue-resistant material.


In this embodiment, the retention frame 106 includes a seal membrane 112 near an end of the frame 106, a pair of tabs 114 along each side of the frame 106 and a removable needle 110. The sealing membrane 112 initially interfaces with the removable needle 110. When the attachment portion 104 is positioned on the user's body, the removable needle 110, as extended through the sealing membrane 112, penetrates the user's skin to insert a cannula 130 (shown in FIG. 1F) through the user's skin. The removable needle 110 can then be removed and discarded. As will be described herein, the sealing membrane 112 will interface with the pump for delivering medicament such as, e.g., insulin, from the pump 102 to the patient through the cannula 130.


The pump 102 includes a cartridge 116 and a drive unit 118 that mate together to form the pump 102. Cartridge 116 is generally a disposable unit containing medicament such as insulin and a drive unit 118 in operation interfaces with cartridge 116 to cause medicament such as insulin from the cartridge to be delivered to the patient. As can be seen in FIG. 1C, cartridge 116 can include an electrical contact 120 for electrically connecting the cartridge 116 and the drive unit 118 and a drive mechanism 122 that mechanically interconnects the cartridge 116 with the drive unit 118 to enable to drive unit 118 to cause insulin to be delivered from the cartridge 116. The drive unit, as shown in FIG. 1F, can include corresponding recesses 124, 126 for accepting the electrical contact 120 and the drive mechanism 122, respectively. Cartridge also includes an opening 128 in a bottom of the cartridge that is aligned with the sealing membrane 112 of the retention frame 106, thereby aligning a cartridge cannula 132 with cannula 130 of the attachment portion 104. In certain embodiments, the drive unit and cartridge can be comprised of, for example, polypropylene, polycarbonate COC, or any other flexible and fatigue-resistant material. Although pump 102 may generally be controlled with a remote device such as, e.g., a smartphone, as described herein, pump 102 may also include a bolus key or button 140, shown here presented on the drive unit 118, for delivering a predetermined quantity of insulin with each push of the key 140.


As shown in FIG. 1D, pump 102 is mated with the retention frame 106 by aligning the pump 102 with the retention frame 106 and pushing it downward onto the frame. Tabs 114 of frame include smaller inner wings 134 and larger outer wings 136. When the pump 102 is pressed downwardly onto the frame 106, the inner wings 134 snap into corresponding recesses 138 on the sides of the pump 102, mechanically locking the pump 102 in place on the frame 106 so it will not inadvertently become dislodged. This snapping action may create an audible “clicking” sound to indicate to the user that the pump 102 is properly mated to the frame 106. As shown, the recesses 138 may be on the drive unit 118. Alternatively, the recesses 138 can be positioned on the cartridge 116. In a further alternative, the recesses 138 can be partially on each of the drive unit 118 and cartridge 116, thereby serving not only to retain the pump 102 on the retention frame 106, but also to provide a further measure holding the two aspects of the pump 102 together. To remove the pump 102 from the cartridge, the outer wings 136 can be pressed downwardly, which will cause the inner wings 134 to slide out from the recesses 138, releasing the pump.



FIGS. 2A-2F depict a patch pump 200 according to another embodiment of the present invention. Patch pump 200 includes similar components to patch pump 100 of FIGS. 1A-1F, and therefore, as with the further embodiments described herein, identical components and functions may not be further described with respect to this embodiment. In this embodiment, the retention frame 206 comprises a surface 207 sized to accommodate the pump 202 and a half clamshell retaining feature 209. The retention frame 206 includes a sealing membrane 212 having a different configuration from sealing membrane 112 of FIGS. 1A-1F and a removable needle 210 shaped to interface with the sealing membrane 212. Note that when the pump 202 is mated with the retention frame 206, the cartridge cannula 232 extends longitudinally into a cartridge opening 211 of the sealing membrane 212 that is different from and aligned perpendicularly to the needle opening 213 through which the needle is inserted.


The pump 202 is attached to the retention frame 206 in this embodiment by a horizontal sliding motion, rather than a vertical motion as with pump 102 and retention frame 106 of the previous embodiment. Retention frame 206 includes a plurality of inwardly projecting tabs 214. These tabs 214 mate with corresponding recesses 238 in the cartridge 216 and/or drive unit 218 of the pump 202 to retain the pump 202 on the retention frame 206. Cartridge 216 can include an undercut portion 217 that slidably mates with the upper rim 205 of retention frame, which creates a smooth outer profile for the combination of the pump 202 and retention frame 206. In other embodiments, the undercut portion 217 can extend onto a portion of drive unit 218 as well. Pump 202 is therefore retained on retention frame 206 primarily by a friction fit, so the pump 202 can be removed by a horizontal force in the opposite direction that overcomes this friction.


Referring now to FIGS. 3A-3F, there can be seen an insulin patch pump 300 according to another embodiment of the invention. In this embodiment, the sealing membrane 312 is positioned generally centrally on a generally flat retention frame 306. After the insertion needle 310 is removed, a quarter-turn cleat 313 of the sealing membrane 312 is exposed. The pump 302 is mated to the quarter-turn cleat 313 of the sealing membrane 312 by a twisting motion in which the pump 302 is initially a quarter-turn offset from the retention frame 306, as shown in FIG. 3D, and is then turned to lock the pump 302 in alignment with the frame 306, as shown in FIG. 3E. A similar turn in the opposite direction would be used to detach the pump 302 from the frame 306. Note that although described as a “quarter-turn” cleat, the degree of angular rotation required to lock and unlock the pump 302 from the retention frame can vary. In one embodiment, as depicted in FIG. 3F, the cartridge 316 can include a cleat 317 for mating with the cleat 313 of the sealing membrane 312 and the drive unit 318 can include a corresponding recess 319 to accommodate the cleat 317 when the cartridge 316 and drive unit 318 are mated. Alternatively, the drive unit 318 can include the cleat and the cartridge 316 can define the recess. In a further embodiment, the cleats 313, 317 could further include mating tabbed features that require downward pressure to engage and upward pressure to disengage during rotation of the pump 302, to ensure that an accidental torque on the pump 302 does not dislodge the pump 302 from the frame 306. The connection described in this embodiment utilizing the turnable cleat improves the reliability of the seal between the pump and the frame/infusion site by creating a wiping effect on the water ingress seal located on the cartridge/pump. This connection also preloads the cartridge to bias the cartridge against the pump such that any excessive compliance between the pump and the cartridge is eliminated. This increases the accuracy of the system because any compliance, looseness, or flexing in the connection between the cartridge and the drive unit can lead to delivery inaccuracy in such syringe/lead screw drive pumps.



FIGS. 4A-4F depict another embodiment of an insulin patch pump 400 according to an embodiment of the present invention. In this embodiment, the retention frame 406 is again generally flat and includes a rail 407 onto which the pump 402 is slidably inserted. The rail 407 terminates at the sealing membrane 412 to properly align the pump 402 with the sealing membrane 412. As can be seen in FIG. 4F, both the cartridge 416 and the drive unit 418 can include slots 417, 419 that mate with rail 407. Rail 407 can include a leading section 409 that is narrower than the rest of rail 407 to enable the pump 402 to be more easily mated with the retention frame 406. Because the slots 417, 419 of the pump 402 can generally be of constant width, the slot 417 at the leading end of the cartridge 416 will be significantly wider than the leading section 409 of the rail, such that far less precision is needed to initially align the rail 407 with the slots 417, 419. As depicted, pump 402 is held onto retention frame 406 via friction and can be removed with a force applied in the opposite horizontal direction. In some embodiments, retention frame 406 can be provided with tabs that mate with recesses in pump 402, similar to any of the previous embodiments.



FIGS. 5A-5D depict an insulin patch pump 500 according to an embodiment of the present invention in which the location of the infusion site is displaced from the location of the pump 502 and retention frame 506. In this embodiment, a standard infusion set 550 is applied to the skin and the patch pump 500 is affixed nearby with adhesive patch 508. A length of tubing 507 extends between the retention frame 506 and the infusion set 550 through which insulin is delivered from the pump 502 to the set 550. In one embodiment, the tubing 507 is preattached to the retention frame 506. In another embodiment, the tubing 507 is preattached to the cartridge 516 of the pump 502. Such an embodiment would enable the pump 502, when desired, to be used while not being connected to the retention frame 506. In such an embodiment, the retention frame 506 and corresponding adhesive patch 508 could be considered optional. Patch pump 500 can provide the user with the flexibility of applying the infusion set 550 and the patch pump 500 in different locations on the skin or not affixing the patch pump 500 to the skin at all. Although this embodiment is depicted as including features for mating the pump 502 and the retention frame 506 similar to those of FIGS. 2A-2F, it should be understood that the mating features of any of the embodiments described herein could be employed.


Referring now to FIGS. 6A-6E, an embodiment of an insulin patch pump 600 is depicted that is adapted to interface directly with a standard infusion set 650. Initially, the infusion set 650 is applied to the patient's skin. The retention frame 606 of the patch pump 600 defines a receiving slot 607 that interfaces directly with the connector 652 of the infusion set 650 to deliver medicament through a cannula of the infusion set. The receiving slot 607 is therefore then mated with the connector 652 and the adhesive patch 608 of the patch pump 600 is affixed to the skin adjacent the infusion set 650. The pump 602 can then be slid onto the retention frame 606 and mated with both the retention frame 606 and the infusion set connector 652. Again, although this embodiment depicts the pump 602 mating with the frame 606 utilizing features similar to those depicted in FIGS. 2A-2F, it should be understood that any of the mating features described herein could be used, though features that utilize a horizontal sliding action to mate the pump to the frame are advantageous in aligning the cartridge cannula with the infusion set 650. In some embodiments, the retainer frame 606 can be identical to the retainer frame 506, such that the same retainer frame can be used interchangeably either displaced from the infusion site or directly on the infusion site, whether with a standard infusion set or an infusion set as disclosed in previous embodiments. The retainer frames of any other embodiments disclosed herein could similarly be used in an interchangeable fashion between local and remote infusion sites.



FIGS. 8A-8F depict a patch pump 800 including a pump 802 and an attachment portion 804 according to another embodiment of the invention. Retention frame 806 of attachment portion 804 includes an insertion portion 812 through which a disposable needle can be inserted to penetrate a sealing membrane and insert a cannula for medicament delivery, as described previously herein. Drive unit 818 of pump includes a drive mechanism 822 that mates with a recess 824 in disposable cartridge 816 to attach the cartridge 816 to the drive unit 818 and provide for delivery of medicament such as insulin from the cartridge 816 to a user through the cannula.


Retention frame 806 in this embodiment also includes a hook portion 814 adjacent one end of the frame and a snap portion 815 adjacent an opposing end of the frame. To mate the pump 802 with the corresponding attachment portion 804, initially hook portion 814 on retention frame 806 is inserted, or hooked, into a recess 838 in the drive unit 818, as shown in FIGS. 8C and 8D. To complete the insertion and mating process, the pump 802 is pivoted downwardly about the hook portion 814 to mate a recess 839 in cartridge 816 with snap portion 815, as shown in FIGS. 8E and 8F. Snap portion 815 can be flexible and resilient such that when the cartridge 816 is mated with the snap portion 815, the snap portion 815 is initially pushed away from the pump 802 and then snaps into place when aligned with the recess 839 to cause an audible clicking or snapping sound that provides an indication to the user that the pump 802 is properly mated to the attachment portion 806. Pump 802 can be released from attachment portion 804 to, for example, enable a user to exchange the cartridge, with one or more tabs 836, which can be depressed to cause one or both of hook portion 814 and snap portion 815 to withdraw from its corresponding recess in pump 802.


Although various embodiments of the insulin patch pumps described herein include a bolus key 140 for delivering a controlled amount of insulin to the user, in certain embodiments it is primarily intended that such patch pumps will be controlled with a remote device. Remote device can include, for example, a smartphone, an electronic tablet, a computer or a dedicated remote controller. In the case of a smartphone and/or an electronic tablet, a dedicated software application may be provided for control of patch pump. One embodiment of a screen shot of a control screen 700 for a patch pump is depicted in FIG. 7. Control screen 700 can include various information and control functions. The control screen may include, for example, a battery life indicator 702, an indicator 704 that indicates the amount of medicament such as, e.g., insulin remaining in the cartridge, a time and date 706 and an indicator 708 that indicates, in this example, an estimate of the amount of insulin remaining in the user's system as well as the amount of time it will take for that insulin to take effect on the user's blood glucose. One control function available from the control screen 700 is a bolus function 710, the selection of which initiates a programmable bolus delivery with the corresponding patch pump. An options function 712 can allow entry into a menu of additional pump options. Various other information and functions that can be incorporated into and/or utilized by control device are disclosed in the various patents and patent applications incorporated by reference herein.


The embodiments described herein generally include a cartridge and drive unit attached to each other in a generally back-to-back relation such that a body of the cartridge and a body of the drive unit are positioned adjacent to each other to each form all or a portion of the outer housing of the pump. It should be noted, however, that various other attachment configurations of the cartridge and housing are within the scope of the present invention. For example, a body of the cartridge and/or drive unit could be attached by being partially or wholly inserted into or partially or wholly contained within the corresponding component. In one specific embodiment, the cartridge can be wholly contained within the drive unit, and can be accessed through, e.g., a latched cover on the drive unit.


Although the embodiments herein are specifically described with respect to the delivery of insulin, delivery of other medicaments, singly or in combination with one another or with insulin, including, for example, glucagon, pramlintide, etc., as well as other applications are also contemplated. Device and method embodiments discussed herein may be used for pain medication, chemotherapy, iron chelation, immunoglobulin treatment, dextrose or saline IV delivery, treatment of various conditions including, e.g., pulmonary hypertension, or any other suitable indication or application. Non-medical applications are also contemplated.


With regard to the above detailed description, like reference numerals used therein may refer to like elements that may have the same or similar dimensions, materials, and configurations. While particular forms of embodiments have been illustrated and described, it will be apparent that various modifications can be made without departing from the spirit and scope of the embodiments herein. Accordingly, it is not intended that the invention be limited by the forgoing detailed description.


The entirety of each patent, patent application, publication, and document referenced herein is hereby incorporated by reference. Citation of the above patents, patent applications, publications and documents is not an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these documents.


Also incorporated herein by reference in their entirety are commonly owned U.S. Pat. Nos. 8,287,495; 8,408,421 and 8,448,824; commonly owned U.S. Patent Publication Nos. 2009/0287180; 2010/0008795; 2010/0071446; 2010/0218586; 2012/0123230; 2013/0053816; 2013/0159456; and 2013/0306191 commonly owned U.S. patent application Ser. Nos. 14/583,274; 14/581,461; 14/581,398; 14/482,521; 14/479,994; 13/800,387; 13/800,453; 13/800,595; 13/801,230; 13/801,274; 13/827,383; 13/827,707; 13/828,958; 13/829,115; 13/832,531; 13/832,841; 13/837,661; 13/837,777; 13/838,084; 13/838,617; 13/841,028; 13/841,432; 13/842,005; 13/842,990 and 13/923,556; and commonly owned U.S. Provisional Application Ser. Nos. 61/874,428, 61/875,979, 61/911,576, 61/920,902, 61/920,914, 61/920,923, 61/920,932 and 61/920,940.


Further incorporated by reference herein in their entirety are U.S. Pat. Nos. 8,601,465; 8,502,662; 8,452,953; 8,451,230; 8,449,523; 8,444,595; 8,343,092; 8,285,328; 8,126,728; 8,117,481; 8,095,123; 7,999,674; 7,819,843; 7,782,192; 7,109,878; 6,997,920; 6,979,326; 6,936,029; 6,872,200; 6,813,519; 6,641,533; 6,554,798; 6,551,276; 6,295,506; and 5,665,065. Modifications may be made to the foregoing embodiments without departing from the basic aspects of the technology. Although the technology may have been described in substantial detail with reference to one or more specific embodiments, changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the technology. The technology illustratively described herein may suitably be practiced in the absence of any element(s) not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation and use of such terms and expressions do not exclude any equivalents of the features shown and described or portions thereof and various modifications are possible within the scope of the technology claimed. Although the present technology has been specifically disclosed by representative embodiments and optional features, modification and variation of the concepts herein disclosed may be made, and such modifications and variations may be considered within the scope of this technology.

Claims
  • 1. A user-wearable infusion pump system, comprising: a user-wearable infusion pump configured to contain a medicament, the user-wearable infusion pump including a button disposed on an outer perimeter of the user-wearable pump configured to selectively cause the user-wearable pump to initiate a medicament delivery operation when the button is pressed;a retention frame configured to selectively retain the user-wearable infusion pump therein, the retention frame including a frame base having a first side and an opposing second side and a first end and opposing second end generally defining a frame perimeter having a shape generally matching the outer perimeter of the user-wearable pump, wherein the retention frame includes a retention wall extending upwardly from the frame base on both the first side and the second side of the frame base, and wherein at least a portion of the retention frame extends inwardly from the frame perimeter to contact and retain the user-wearable pump on the retention frame when the user-wearable pump is disposed on the frame base, andwherein the button is accessible when the user-wearable pump is retained in the retention frame adjacent the frame perimeter through an opening disposed adjacent one of the first end or the second end of the frame base.
  • 2. The user-wearable infusion pump system of claim 1, wherein the button is accessible when the user-wearable pump is retained in the retention frame at one of the first end or the second end of the frame base.
  • 3. The user-wearable infusion pump system of claim 2, wherein the retention frame does not include an upwardly extending wall at least at a portion of the one of the first end or the second end.
  • 4. The user-wearable infusion pump system of claim 1, wherein the retention frame is configured to selectively retain the user-wearable infusion pump therein primarily via friction.
  • 5. The user-wearable infusion pump system of claim 1, wherein the retention frame is configured to slidably receive the user-wearable infusion pump between the retention walls.
  • 6. The user-wearable infusion pump system of claim 1, further comprising tubing configured to extend between the user-wearable infusion pump and an infusion site displaced from a location of the retention frame.
  • 7. The user-wearable infusion pump system of claim 6, wherein the tubing is integrally attached to the pump.
  • 8. The user-wearable infusion pump system of claim 1, further comprising an adhesive patch configured to attach the retention frame to a body of a user.
  • 9. The user-wearable infusion pump system of claim 1, further comprising a remote control device configured to control operation of the user-wearable infusion pump.
  • 10. The user-wearable infusion pump system of claim 9, wherein the remote control device is a smartphone.
  • 11. The user-wearable infusion pump of claim 9, wherein the remote control device is a dedicated remote controller.
  • 12. The user-wearable infusion pump of claim 1, wherein a distance between the first end and the second end of the frame base is greater than a distance between the first side and the second side of the frame base.
  • 13. A retention frame for selectively retaining a user-wearable infusion pump, comprising: a frame base having a first side and an opposing second side and a first end and opposing second end generally defining a frame perimeter having a shape generally matching an outer perimeter of a user-wearable pump to be retained therein;a first retention wall extending upwardly from the frame base on the first side of the frame base; anda second retention wall extending upwardly from the frame base on the second side of the frame base;an opening disposed adjacent the frame perimeter at one of the first end or the second end of the frame base configured to enable access to a button disposed on an outer perimeter of the user-wearable infusion pump when the user-wearable infusion pump is disposed on the frame base,wherein at least a portion of the retention frame extends inwardly to contact and retain the user-wearable pump on the retention frame when the user-wearable pump is disposed on the frame base.
  • 14. The retention frame of claim 13, wherein the retention frame does not include an upwardly extending wall at least at a portion of the one of the first end or the second end of the frame base.
  • 15. The retention frame of claim 14, wherein the opening is defined at the at least one of the first end or the second end where the retention frame does not include an upwardly extending wall.
  • 16. The retention frame of claim 13, wherein the retention frame is configured to selectively retain the user-wearable infusion pump therein primarily via friction.
  • 17. The retention frame of claim 13, wherein the retention frame is configured to slidably receive the user-wearable infusion pump between the first retention wall and the second retention wall.
  • 18. The retention frame of claim 13, wherein a distance between the first end and the second end of the frame base is greater than a distance between the first side and the second side of the frame base.
RELATED APPLICATIONS

This application is a continuation of application Ser. No. 14/707,851 filed May 8, 2015, which claims the benefit of U.S. Provisional Application No. 61/990,501 filed May 8, 2014, each of which is incorporated herein in its entirety by reference.

US Referenced Citations (306)
Number Name Date Kind
4908017 Howson et al. Mar 1990 A
5050612 Matsumura Sep 1991 A
5053189 Chrise et al. Oct 1991 A
5665065 Colman et al. Sep 1997 A
6280408 Sipin Aug 2001 B1
6295506 Heinonen et al. Sep 2001 B1
6551276 Mann et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6589229 Connelly et al. Jul 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6699218 Flaherty et al. Mar 2004 B2
6702779 Connelly et al. Mar 2004 B2
6813519 Lebel et al. Nov 2004 B2
6872200 Mann et al. Mar 2005 B2
6936029 Mann et al. Aug 2005 B2
6940209 Henderson Sep 2005 B2
6952604 Denuzzio et al. Oct 2005 B2
6955819 Zhang et al. Oct 2005 B2
6979326 Mann et al. Dec 2005 B2
6997920 Mann et al. Feb 2006 B2
7008399 Larsen et al. Mar 2006 B2
7056179 Courtney Jun 2006 B2
7109878 Mann et al. Sep 2006 B2
7170214 Henderson et al. Jan 2007 B2
7250037 Shermer et al. Jul 2007 B2
7309943 Henderson et al. Dec 2007 B2
7339306 Henderson Mar 2008 B2
7426408 Denuzzio et al. Sep 2008 B2
7429258 Angel et al. Sep 2008 B2
7455663 Bikovsky Nov 2008 B2
7464010 Yang et al. Dec 2008 B2
7534226 Mernoe et al. May 2009 B2
7569050 Moberg et al. Aug 2009 B2
7632247 Adams Dec 2009 B2
7641649 Moberg et al. Jan 2010 B2
7682338 Griffin Mar 2010 B2
7686787 Moberg et al. Mar 2010 B2
7699833 Moberg et al. Apr 2010 B2
7708717 Estes et al. May 2010 B2
7713262 Adams et al. May 2010 B2
7717903 Estes et al. May 2010 B2
7736338 Kavazov et al. Jun 2010 B2
7736344 Moberg et al. Jun 2010 B2
7744589 Mounce et al. Jun 2010 B2
7776030 Estes et al. Aug 2010 B2
7782192 Jeckelmann et al. Aug 2010 B2
7786648 Xu et al. Aug 2010 B2
7789857 Moberg et al. Sep 2010 B2
7794426 Briones et al. Sep 2010 B2
7794427 Estes et al. Sep 2010 B2
7794428 Estes et al. Sep 2010 B2
7794434 Mounce et al. Sep 2010 B2
7806868 De Polo et al. Oct 2010 B2
7811262 Moberg et al. Oct 2010 B2
7815609 Hines et al. Oct 2010 B2
7819343 Paul et al. Oct 2010 B2
7828528 Estes et al. Nov 2010 B2
7828764 Moberg et al. Nov 2010 B2
7833196 Estes et al. Nov 2010 B2
7875022 Wenger et al. Jan 2011 B2
7879026 Estes et al. Feb 2011 B2
7887511 Mernøe et al. Feb 2011 B2
7887512 Estes et al. Feb 2011 B2
7892199 Mhatre et al. Feb 2011 B2
7905868 Moberg et al. Mar 2011 B2
7933780 De La Huerga Apr 2011 B2
7935076 Estes et al. May 2011 B2
7935105 Miller et al. May 2011 B2
7938797 Estes May 2011 B2
7938803 Mernoe et al. May 2011 B2
7945452 Fathallah et al. May 2011 B2
7955305 Moberg et al. Jun 2011 B2
7959598 Estes Jun 2011 B2
7959715 Kavazov et al. Jun 2011 B2
7963954 Kavazov Jun 2011 B2
7976500 Adams et al. Jul 2011 B2
7976505 Hines et al. Jul 2011 B2
7981076 Sullivan et al. Jul 2011 B2
7981084 Estes et al. Jul 2011 B2
7981102 Patel et al. Jul 2011 B2
7999674 Kamen Aug 2011 B2
8032226 Miller et al. Oct 2011 B2
8062256 Carter et al. Nov 2011 B2
8078983 Davis et al. Dec 2011 B2
8095123 Gray Jan 2012 B2
8105279 Mernoe et al. Jan 2012 B2
8109921 Estes et al. Feb 2012 B2
8114350 Silver et al. Feb 2012 B1
8115600 Stevenson et al. Feb 2012 B2
8117481 Anselmi et al. Feb 2012 B2
8126728 Dicks et al. Feb 2012 B2
8128597 Cross et al. Mar 2012 B2
8187228 Bikovsky May 2012 B2
8211062 Estes et al. Jul 2012 B2
8211093 Miller et al. Jul 2012 B2
8217533 Jones et al. Jul 2012 B2
8221385 Estes Jul 2012 B2
8231572 Carter et al. Jul 2012 B2
8234126 Estes Jul 2012 B1
8277435 Estes Oct 2012 B2
8282601 Mernoe et al. Oct 2012 B2
8285328 Caffey et al. Oct 2012 B2
8287487 Estes Oct 2012 B2
8287495 Michaud et al. Oct 2012 B2
8287514 Miller et al. Oct 2012 B2
8299733 Sattler et al. Oct 2012 B2
8304960 Sattler et al. Nov 2012 B2
8323188 Tran Dec 2012 B2
8328754 Estes et al. Dec 2012 B2
8343092 Rush et al. Jan 2013 B2
8344847 Moberg et al. Jan 2013 B2
8361030 Carter Jan 2013 B2
8408421 Diperna Apr 2013 B2
8409142 Causey Apr 2013 B2
8414523 Blomquist et al. Apr 2013 B2
8414563 Kamen et al. Apr 2013 B2
8444595 Brukalo et al. May 2013 B2
8448824 Diperna May 2013 B2
8449523 Brukalo et al. May 2013 B2
8450905 Guidarelli et al. May 2013 B2
8451230 Celentano et al. May 2013 B2
8452953 Buck et al. May 2013 B2
8454557 Qi et al. Jun 2013 B1
8454562 Sims Jun 2013 B1
8454575 Estes et al. Jun 2013 B2
8454581 Estes et al. Jun 2013 B2
8466637 Guidarelli et al. Jun 2013 B2
8469920 Mernoe et al. Jun 2013 B2
8502662 Pohlman et al. Aug 2013 B2
8517991 Clemente Aug 2013 B2
8573027 Rosinko et al. Nov 2013 B2
8601465 Bernstein et al. Dec 2013 B2
8728034 Yodfat et al. May 2014 B2
8740847 Levesque Jun 2014 B2
8801655 Mernoe Aug 2014 B2
8852152 Tverskoy Oct 2014 B2
8986253 Diperna Mar 2015 B2
9101714 Miyazaki Aug 2015 B2
9114210 Estes Aug 2015 B2
9259531 Kamen Feb 2016 B2
9308319 Mernoe Apr 2016 B2
9362851 Xu et al. Jun 2016 B2
9968729 Estes May 2018 B2
9993595 Michaud et al. Jun 2018 B2
10279106 Cook et al. May 2019 B1
10279107 Michaud May 2019 B2
10357603 Michaud et al. Jul 2019 B2
20030199378 Saviano Oct 2003 A1
20040092865 Flaherty et al. May 2004 A1
20050177111 Ozeri et al. Aug 2005 A1
20060229557 Fathallah et al. Oct 2006 A1
20060250260 Albert Nov 2006 A1
20060253086 Moberg et al. Nov 2006 A1
20070073236 Mernoe et al. Mar 2007 A1
20070156092 Estes et al. Jul 2007 A1
20070167905 Estes et al. Jul 2007 A1
20070167912 Causey et al. Jul 2007 A1
20070173762 Estes et al. Jul 2007 A1
20070179444 Causey et al. Aug 2007 A1
20070219480 Kamen et al. Sep 2007 A1
20070219496 Kamen et al. Sep 2007 A1
20070219597 Kamen et al. Sep 2007 A1
20070228071 Kamen et al. Oct 2007 A1
20080045902 Estes et al. Feb 2008 A1
20080045903 Estes et al. Feb 2008 A1
20080045904 Estes et al. Feb 2008 A1
20080045931 Estes et al. Feb 2008 A1
20080051697 Mounce et al. Feb 2008 A1
20080051698 Mounce et al. Feb 2008 A1
20080051709 Mounce et al. Feb 2008 A1
20080051711 Mounce et al. Feb 2008 A1
20080051716 Stutz Feb 2008 A1
20080051727 Moberg et al. Feb 2008 A1
20080051765 Mounce Feb 2008 A1
20080097291 Hanson et al. Apr 2008 A1
20080097327 Bente et al. Apr 2008 A1
20080097375 Bikovsky Apr 2008 A1
20080097381 Moberg et al. Apr 2008 A1
20080215035 Yodfat et al. Sep 2008 A1
20080269680 Ibranyan et al. Oct 2008 A1
20080269681 Kavazov et al. Oct 2008 A1
20080269682 Kavazov et al. Oct 2008 A1
20080294094 Mhatre et al. Nov 2008 A1
20080294108 Briones et al. Nov 2008 A1
20080294109 Estes et al. Nov 2008 A1
20080294142 Patel et al. Nov 2008 A1
20090036870 Mounce et al. Feb 2009 A1
20090067989 Estes et al. Mar 2009 A1
20090069745 Estes et al. Mar 2009 A1
20090069746 Miller et al. Mar 2009 A1
20090069749 Miller et al. Mar 2009 A1
20090069784 Estes et al. Mar 2009 A1
20090069785 Miller et al. Mar 2009 A1
20090069787 Estes et al. Mar 2009 A1
20090082728 Bikovsky Mar 2009 A1
20090124994 Roe May 2009 A1
20090156990 Wenger et al. Jun 2009 A1
20090171324 Chong et al. Jul 2009 A1
20090177142 Blomquist et al. Jul 2009 A1
20090177991 Davis et al. Jul 2009 A1
20090254037 Bryant, Jr. et al. Oct 2009 A1
20090259183 Chong et al. Oct 2009 A1
20090259198 Chong et al. Oct 2009 A1
20090259209 Chong et al. Oct 2009 A1
20090270811 Mounce et al. Oct 2009 A1
20090275887 Estes Nov 2009 A1
20090287180 Diperna Nov 2009 A1
20090326458 Chong et al. Dec 2009 A1
20100008795 Diperna Jan 2010 A1
20100010647 Schroeder et al. Jan 2010 A1
20100016791 Chong et al. Jan 2010 A1
20100049164 Estes Feb 2010 A1
20100071446 Brown Mar 2010 A1
20100094251 Estes Apr 2010 A1
20100152658 Hanson et al. Jun 2010 A1
20100152674 Kavazov et al. Jun 2010 A1
20100174266 Estes Jul 2010 A1
20100185142 Kamen et al. Jul 2010 A1
20100185175 Kamen et al. Jul 2010 A1
20100198183 Lanigan et al. Aug 2010 A1
20100218586 Rosinko et al. Sep 2010 A1
20100228186 Estes et al. Sep 2010 A1
20100241065 Moberg et al. Sep 2010 A1
20100256565 Mernøe et al. Oct 2010 A1
20100261987 Kamath et al. Oct 2010 A1
20100331824 Moberg et al. Dec 2010 A1
20110006876 Moberg et al. Jan 2011 A1
20110009725 Hill et al. Jan 2011 A1
20110009813 Rankers Jan 2011 A1
20110009823 Chong et al. Jan 2011 A1
20110009825 Chong et al. Jan 2011 A1
20110030845 Chong et al. Feb 2011 A1
20110040247 Mandro et al. Feb 2011 A1
20110040251 Blomquist et al. Feb 2011 A1
20110047499 Mandro et al. Feb 2011 A1
20110060280 Caffey et al. Mar 2011 A1
20110082439 Wenger et al. Apr 2011 A1
20110105955 Yudovsky et al. May 2011 A1
20110112504 Causey et al. May 2011 A1
20110118662 Mhatre et al. May 2011 A1
20110160650 Chong et al. Jun 2011 A1
20110160654 Hanson et al. Jun 2011 A1
20110160666 Hanson et al. Jun 2011 A1
20110160678 Chong et al. Jun 2011 A1
20110178461 Chong et al. Jul 2011 A1
20110190694 Lanier, Jr. et al. Aug 2011 A1
20110190700 Kavazov et al. Aug 2011 A1
20110192478 Chong et al. Aug 2011 A1
20110213306 Hanson et al. Sep 2011 A1
20110213329 Yodfat Sep 2011 A1
20120029708 Miller et al. Feb 2012 A1
20120123230 Brown et al. May 2012 A1
20120185267 Kamen et al. Jul 2012 A1
20120203178 Tverskoy Aug 2012 A1
20120302991 Blomquist Nov 2012 A1
20130012917 Miller et al. Jan 2013 A1
20130053816 Diperna et al. Feb 2013 A1
20130117696 Robertson May 2013 A1
20130159456 Daoud et al. Jun 2013 A1
20130231711 Kaib Sep 2013 A1
20130283196 Farnan et al. Oct 2013 A1
20130306191 Metzmaker et al. Nov 2013 A1
20130324920 Kohli et al. Dec 2013 A1
20130324928 Kruse Dec 2013 A1
20130331778 Kruse et al. Dec 2013 A1
20130331790 Brown et al. Dec 2013 A1
20130332874 Rosinko et al. Dec 2013 A1
20140012511 Mensinger et al. Jan 2014 A1
20140054883 Lanigan et al. Feb 2014 A1
20140273042 Saint Sep 2014 A1
20140276409 Rosinko et al. Sep 2014 A1
20140276419 Rosinko et al. Sep 2014 A1
20140276420 Rosinko Sep 2014 A1
20140276423 Lecanu-Fayet Sep 2014 A1
20140276531 Walsh Sep 2014 A1
20140276537 Kruse Sep 2014 A1
20140276538 Michaud Sep 2014 A1
20140276553 Rosinko et al. Sep 2014 A1
20140276556 Saint et al. Sep 2014 A1
20140276569 Kruse Sep 2014 A1
20140276570 Saint Sep 2014 A1
20140276571 Ludolph Sep 2014 A1
20140276574 Saint Sep 2014 A1
20140296784 Lopez Oct 2014 A1
20140378898 Rosinko Dec 2014 A1
20150072613 Swanson Mar 2015 A1
20150073337 Saint et al. Mar 2015 A1
20150182695 Rosinko Jul 2015 A1
20160136357 Yang May 2016 A1
20160157759 Yang Jun 2016 A1
20160157765 Zhu Jun 2016 A1
20160158436 Yang Jun 2016 A1
20160199572 Yang Jul 2016 A1
20160256622 Day Sep 2016 A1
20160339197 Meyerhoff et al. Nov 2016 A1
20170049957 Michaud Feb 2017 A1
20170173261 O'Connor Jun 2017 A1
20170290976 Murphy et al. Oct 2017 A1
20180071454 Betts et al. Mar 2018 A1
20180093039 Este Apr 2018 A1
20180137252 Mairs May 2018 A1
20180137938 Vaddiraju May 2018 A1
20180161498 Este Jun 2018 A1
20180264189 Michaud et al. Sep 2018 A1
20180336208 Kim Nov 2018 A1
20190240398 Seitz et al. Aug 2019 A1
Foreign Referenced Citations (12)
Number Date Country
101745163 Dec 2013 CN
WO-2008103175 Aug 2008 WO
WO-2008144693 Nov 2008 WO
WO-2008144695 Nov 2008 WO
WO-2008144697 Nov 2008 WO
WO-2008144698 Nov 2008 WO
WO-2009013736 Jan 2009 WO
WO-2009016636 Feb 2009 WO
WO-2009032399 Mar 2009 WO
WO-2009032400 Mar 2009 WO
WO-2009032402 Mar 2009 WO
WO-2009035759 Mar 2009 WO
Non-Patent Literature Citations (1)
Entry
Application and File history for U.S. Appl. No. 14/707,851, filed May 8, 2015. Inventors: Cook et al.
Related Publications (1)
Number Date Country
20190351134 A1 Nov 2019 US
Provisional Applications (1)
Number Date Country
61990501 May 2014 US
Continuations (1)
Number Date Country
Parent 14707851 May 2015 US
Child 16398402 US